DL-AP5 (2-APV) 是一种竞争性的NMDA(N-methyl-D-aspartate) 受体拮抗剂。DL-AP5 表现出明显的镇痛活性。DL-AP5 可特异性阻断兔视网膜的通道。
| 生物活性 | DL-AP5 (2-APV) is a competitiveNMDA(N-methyl-D-aspartate) receptor antagonist. DL-AP5 shows significantly antinociceptive activity. DL-AP5 specifically blocks on channels in the rabbit retina[1][2][3]. |
| IC50& Target | |
体外研究
(In Vitro) | DL-AP5 (100 μM) partially prevents glutamate-induced increase in Arc/Arg3.1 protein levels[5].
DL-AP5 decreases the NMDA-induced Arc/Arg3.1 upregulation[5].
|
体内研究
(In Vivo) | DL-AP5 (0-10 μg/rat, Intra-CA1) significantly decreases the effect of NMDA[3].
DL-AP5 (0-10 nmol, Intracerebroventricular injection) causes a dose-dependent increase in food consumption[4].
DL-AP5 (5 nmol, Intracerebroventricular injection) attenuates the decreased food consumption induced by the intracerebroventricular injection of ghrelin[4].
| Animal Model: | Male Wistar rats (180-230 g)[3] | | Dosage: | 1, 3.2 and 10 μg/rat | | Administration: | Injected into the intra-dorsal hippocampal (intra-CA1) immediately after shock administration, once | | Result: | Significantly decreased the effect of NMDA (10-2μg/rat, intra-CA1) with significant interaction. |
| Animal Model: | Broilers cockerels (3-h fooddeprived (FD3), n=8 for each group)[4] | | Dosage: | 0, 2.5, 5, and 10 nmol; in a volume of 10 μL | | Administration: | Intracerebroventricular injection | | Result: | Caused a dose-dependent increase in food consumption which was significant for 5 and 10 nmol doses. |
| Animal Model: | Broilers cockerels (3-h fooddeprived (FD3), n=8 for each group)[4] | | Dosage: | 5 nmol | | Administration: | Intracerebroventricular injection, followed by ghrelin (0.6 nmol) | | Result: | Attenuated the decreased food consumption induced by the intracerebroventricular injection of ghrelin. |
|
| 分子量 | |
| 性状 | |
| Formula | |
| CAS 号 | |
| 运输条件 | Room temperature in continental US; may vary elsewhere. |
| 储存方式 | | Powder | -20°C | 3 years | | In solvent | -80°C | 6 months | | -20°C | 1 month |
|
| 溶解性数据 | In Vitro: H2O : 33.33 mg/mL(169.08 mM;ultrasonic and warming and heat to 60℃) 配制储备液 | 1 mM | 5.0728 mL | 25.3640 mL | 50.7279 mL | | 5 mM | 1.0146 mL | 5.0728 mL | 10.1456 mL | | 10 mM | 0.5073 mL | 2.5364 mL | 5.0728 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80℃, 6 months; -20℃, 1 month。-80℃ 储存时，请在 6 个月内使用，-20℃ 储存时，请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液，再依次添加助溶剂： ——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂： PBS Solubility: 50 mg/mL (253.64 mM); Clear solution; Need ultrasonic
*以上所有助溶剂都可在本网站选购。 |
m.cnreagent.com